GoldenWing (Suzhou) Medical Technology Co., Ltd.
SEARCH
GoldenWing Medical
GoldenWing (Suzhou) Medical Technology Co., Ltd.
As a core member of Medphoenix Medical Group, GoldenWing Medical was founded in 2018 by renowned Chinese doctors with a mission to become a global leading one-stop service provider for innovative medical devices, offering specialised services including medical research, pre-clinical large animal testing, clinical trials and global registration. We have gathered more than 200 medical doctors with PhD and/or MSc degrees from hospitals in the country and abroad. Our laboratories cover an area of 18,000 square metres and are equipped with a complete set of high-end medical equipment, including renowned brands such as Philips, Siemens, GE, Solin, Mindray, etc. The certification system includes OECD GLP, FDA GLP and CNAS-CL06. We've served over 1,000 domestic and international customers and over 100 partner hospitals. In the field of preclinical studies, we have been ranked No.1 in China.
Development History
2017-2019
2017
Settled in Taizhou China Medical City
2018
Officially put into operation
2019
Obtained angel round financing from the Pharmaceutical City Fund
2020-2021
2020
Complete the Pre-A round of funding.
Receive support from industrial capital.
Receive support from industrial capital.
2021
GoldenWing is established.
2022-2023
2022
Complete nearly RMB 100 million in A rou.
Complete the construction of the Suzhou laboratory.
Complete the construction of the Suzhou laboratory.
2023
Complete the construction of a 13,000 square meter laboratory in Taizhou.
Clinical CRO completes its layout.
Clinical CRO completes its layout.
2024
2024
• In June 2024, we successfully obtained CNAS accreditation, further enhancing the reliability of its experimental services.
• In July 2024, we successively undertook GLP pre-test and formal experimental projects at home and abroad.
• In August-September 2024, the “Medical Device Management Law of the People's Republic of China (Draft for Opinion)” solicited for comments, and Medphoenix group put forward the revised opinions on non-clinical research of medical devices and submitted them to the relevant departments.
• In September 2024, the company successfully passed the on-site review of the American customer in accordance with the 21 CFR Part 58 GLP, and carried out the test.
• In October 2024, successfully passed the on-site review and certification of the OECD GLP expert group, and became the world's first batch of OECD GLP laboratories focusing on large animal testing of medical devices only, officially Undertake preclinical large animal testing for US FDA 510k, PMA declaration and EU CE (MDR) declaration.
• In July 2024, we successively undertook GLP pre-test and formal experimental projects at home and abroad.
• In August-September 2024, the “Medical Device Management Law of the People's Republic of China (Draft for Opinion)” solicited for comments, and Medphoenix group put forward the revised opinions on non-clinical research of medical devices and submitted them to the relevant departments.
• In September 2024, the company successfully passed the on-site review of the American customer in accordance with the 21 CFR Part 58 GLP, and carried out the test.
• In October 2024, successfully passed the on-site review and certification of the OECD GLP expert group, and became the world's first batch of OECD GLP laboratories focusing on large animal testing of medical devices only, officially Undertake preclinical large animal testing for US FDA 510k, PMA declaration and EU CE (MDR) declaration.
If you are interested in working with us, please complete the form below and we will contact you
as soon as possible.
GoldenWing (Suzhou) Medical Technology Co., Ltd.
✖